| Year |
Citation |
Score |
| 2017 |
Lin Y, Satani N, Hammoudi N, Pisaneschi F, Leonard P, Maxwell D, Peng Z, Link T, Gilbert LIR, Bosajou A, Sun D, Marszalek J, Sun Y, McMurray JS, Mandal PK, ... ... Bornmann W, et al. Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A39 |
0.392 |
|
| 2016 |
Leonard PG, Satani N, Maxwell D, Lin YH, Hammoudi N, Peng Z, Pisaneschi F, Link TM, Lee GR, Sun D, Prasad BA, Di Francesco ME, Czako B, Asara JM, Wang YA, Bornmann W, et al. SF2312 is a natural phosphonate inhibitor of enolase. Nature Chemical Biology. PMID 27723749 DOI: 10.1038/Nchembio.2195 |
0.337 |
|
| 2016 |
Velez J, Pan R, Lee JT, Enciso L, Suarez M, Duque JE, Jaramillo D, Lopez C, Morales L, Bornmann W, Konopleva M, Krystal G, Andreeff M, Samudio I. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget. PMID 27283492 DOI: 10.18632/Oncotarget.9843 |
0.304 |
|
| 2016 |
Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G, Xie XJ, Sumer BD, Boothman DA, Yordy JS. NQO1-mediated tumor-selective lethality and radiosensitization for head and neck cancer. Molecular Cancer Therapeutics. PMID 27196777 DOI: 10.1158/1535-7163.Mct-15-0765 |
0.313 |
|
| 2016 |
Lin Y, Satani N, Hammoudi N, Pisaneschi F, Leonard P, Maxwell D, Peng Z, Link T, Lee G, Sun D, Marszalek J, Sun Y, McMurray J, Mandal P, Di Francesco M, ... Bornmann W, et al. POMHEX, a cell-permeable enolase inhibitor for collateral lethality targeting of ENO1-deleted glioblastoma European Journal of Cancer. 69: S124. DOI: 10.1016/S0959-8049(16)32968-9 |
0.306 |
|
| 2014 |
Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells. Cell Cycle (Georgetown, Tex.). 13: 2587-99. PMID 25486199 DOI: 10.4161/15384101.2015.942210 |
0.306 |
|
| 2014 |
Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Molecular Cancer Therapeutics. 13: 1848-59. PMID 24739393 DOI: 10.1158/1535-7163.Mct-13-0576 |
0.348 |
|
| 2014 |
Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, ... ... Bornmann WG, et al. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxidants & Redox Signaling. 21: 237-50. PMID 24512128 DOI: 10.1089/Ars.2013.5462 |
0.305 |
|
| 2014 |
Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, ... ... Bornmann WG, et al. Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). Bioorganic & Medicinal Chemistry. 22: 1450-8. PMID 24457091 DOI: 10.1016/J.Bmc.2013.12.048 |
0.373 |
|
| 2014 |
Pal A, Sung B, Bhanu Prasad BA, Schuber PT, Prasad S, Aggarwal BB, Bornmann WG. Curcumin glucuronides: Assessing the proliferative activity against human cell lines Bioorganic and Medicinal Chemistry. 22: 435-439. PMID 24280069 DOI: 10.1016/J.Bmc.2013.11.006 |
0.346 |
|
| 2014 |
Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Pal A, Wang S, Balatoni J, Ghosh P, Lim ST, Volgin A, Shavrin A, Alauddin MM, Gelovani JG, Bornmann WG. Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level. Bioorganic & Medicinal Chemistry. 22: 623-32. PMID 24280068 DOI: 10.1016/J.Bmc.2013.10.040 |
0.341 |
|
| 2014 |
Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang J. RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B. Oncogene. 33: 2385-94. PMID 23708659 DOI: 10.1038/Onc.2013.182 |
0.307 |
|
| 2014 |
Huang X, Moore Z, Luo X, Chakrabarti G, Ilcheva M, Brekken R, Burma S, Gao J, Deberardinis R, Bornmann W, Hergenrother P, Boothman DA. Abstract 787: DNA repair and metabolism inhibitors are tumor-selective when combined with NQO1 bioactivatable drugs for therapy against pancreatic and nonsmall cell lung cancers Cancer Research. 74: 787-787. DOI: 10.1158/1538-7445.Am2014-787 |
0.321 |
|
| 2014 |
Zuo M, Maxwell D, Prasad BAB, Peng Z, Bornmann W, Javle MM. Abstract 5361: Development of targeted inhibitors against RecQ1 helicase Cancer Research. 74: 5361-5361. DOI: 10.1158/1538-7445.Am2014-5361 |
0.398 |
|
| 2014 |
Bornmann WG, Peng Z, Maxwell D, Sun D, Bhanu BA, Talpaz M, Donato N, Levitzki A. Abstract 2698: Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I) Cancer Research. 74: 2698-2698. DOI: 10.1158/1538-7445.Am2014-2698 |
0.373 |
|
| 2014 |
Chiao PJ, Zhuang Z, Xia Q, Schuber PT, Sun D, Peng Z, Maxwell DS, Bornmann WG. Abstract 1727: Development of novel TAK1 inhibitors for pancreatic cancer Cancer Research. 74: 1727-1727. DOI: 10.1158/1538-7445.Am2014-1727 |
0.373 |
|
| 2013 |
Pal A, Peng Z, Schuber PT, Bhanu Prasad BA, Bornmann WG. Asymmetric Synthesis of the C1-C6 Portion of the Psymberin Using an Evans Chiral Auxiliary. Tetrahedron Letters. 54: 5555-5567. PMID 25110364 DOI: 10.1016/J.Tetlet.2013.05.153 |
0.304 |
|
| 2013 |
Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K. Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation. Plos One. 8: e77262. PMID 24204784 DOI: 10.1371/Journal.Pone.0077262 |
0.539 |
|
| 2013 |
Vanderslice P, Biediger RJ, Woodside DG, Brown WS, Khounlo S, Warier ND, Gundlach CW, Caivano AR, Bornmann WG, Maxwell DS, McIntyre BW, Willerson JT, Dixon RA. Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion. The Journal of Biological Chemistry. 288: 19414-28. PMID 23703610 DOI: 10.1074/Jbc.M113.479634 |
0.322 |
|
| 2013 |
Arumugam T, Ramachandran V, Sun D, Peng Z, Pal A, Maxwell DS, Bornmann WG, Logsdon CD. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Molecular Cancer Therapeutics. 12: 654-62. PMID 23303403 DOI: 10.1158/1535-7163.Mct-12-0771 |
0.309 |
|
| 2013 |
Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorganic & Medicinal Chemistry. 21: 932-9. PMID 23294827 DOI: 10.1016/J.Bmc.2012.12.008 |
0.32 |
|
| 2013 |
Maxwell DS, Sun D, Peng Z, Qi W, McConkey D, Abbruzzese JL, Bornmann WG. Abstract B101: Design and optimization of a new series of HSP70 inhibitors for use in the treatment of pancreatic cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B101 |
0.367 |
|
| 2012 |
Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex Leukemia. 26: 778-787. PMID 22064351 DOI: 10.1038/Leu.2011.287 |
0.36 |
|
| 2012 |
Zhou Y, Tozzi F, Xia L, Fan F, Lu J, Maxwell D, Gao G, Bornmann W, Weihua Z, Ellis LM. Abstract B64: Development of a novel strategy to overcome drug resistance by targeting ATP citrate lyase and de novo lipogenesis in colorectal cancer cells Clinical Cancer Research. 18: B64-B64. DOI: 10.1158/1078-0432.Mechres-B64 |
0.334 |
|
| 2011 |
Peng Z, Pal A, Han D, Wang S, Maxwell D, Levitzki A, Talpaz M, Donato NJ, Bornmann W. Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. Bioorganic & Medicinal Chemistry. 19: 7194-204. PMID 22036213 DOI: 10.1016/J.Bmc.2011.09.057 |
0.379 |
|
| 2011 |
Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination Cellular Signalling. 23: 2076-2085. PMID 21855629 DOI: 10.1016/J.Cellsig.2011.08.002 |
0.33 |
|
| 2011 |
Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 117: 4424-38. PMID 21491416 DOI: 10.1002/Cncr.26073 |
0.311 |
|
| 2011 |
Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Research. 71: 3658-68. PMID 21444672 DOI: 10.1158/0008-5472.Can-10-3647 |
0.301 |
|
| 2011 |
Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis Blood. 117: 3151-3162. PMID 21248063 DOI: 10.1182/Blood-2010-03-276477 |
0.35 |
|
| 2011 |
Nawrocki ST, Espitia CM, Kelly KR, Bornmann WG, Carew JS. Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Acute Myeloid Leukemia Blood. 118: 84-84. DOI: 10.1182/Blood.V118.21.84.84 |
0.35 |
|
| 2011 |
Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA. Abstract LB-400: STAT3 mediates resistance to MEK inhibitor through microRNA miR-17 Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-400 |
0.308 |
|
| 2011 |
Lan PV, Tamayo AT, Li C, Sun D, Pal A, Peng Z, Maxwell D, Ford RJ, Bornmann WG. Abstract A129: Development of turmerax therapeutic compounds in aggressive, refractory B cell non-Hodgkin's lymphoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A129 |
0.329 |
|
| 2011 |
Kupferman ME, Lee J, Sun D, Peng Z, Maxwell DS, Bornmann WG. Abstract A122: Therapeutic modulation of Trkb in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A122 |
0.39 |
|
| 2010 |
Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. Plos One. 5: e14124. PMID 21124782 DOI: 10.1371/Journal.Pone.0014124 |
0.335 |
|
| 2010 |
Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis Cancer Research. 70: 9265-9276. PMID 21045142 DOI: 10.1158/0008-5472.Can-10-1530 |
0.373 |
|
| 2010 |
Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation Oncogene. 29: 5619-5629. PMID 20676141 DOI: 10.1038/Onc.2010.295 |
0.33 |
|
| 2010 |
Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Molecular Cancer Therapeutics. 9: 2026-36. PMID 20606045 DOI: 10.1158/1535-7163.Mct-10-0238 |
0.361 |
|
| 2010 |
Swimm AI, Bornmann W, Jiang M, Imperiale MJ, Lukacher AE, Kalman D. Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus. Journal of Virology. 84: 4243-51. PMID 20181697 DOI: 10.1128/Jvi.00129-10 |
0.307 |
|
| 2010 |
Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann WG, Quintás-Cardama A, Roulston D, Talpaz M, Peterson LF, Donato NJ. ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells Leukemia. 24: 869-872. PMID 20111070 DOI: 10.1038/Leu.2009.300 |
0.314 |
|
| 2010 |
Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction Journal of Clinical Investigation. 120: 142-156. PMID 20038799 DOI: 10.1172/Jci38942 |
0.319 |
|
| 2010 |
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 184-94. PMID 20028751 DOI: 10.1158/1078-0432.Ccr-09-1180 |
0.347 |
|
| 2010 |
Xie X, Bartholomeusz C, Maxwell D, Peng Z, Kazansky A, Bornmann W, Ueno N. Abstract P6-15-20: Development of PEA-15-Based Therapy in Breast Cancer in a Preclinical Study Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-15-20 |
0.31 |
|
| 2009 |
Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Molecular Cancer Therapeutics. 8: 1157-68. PMID 19417153 DOI: 10.1158/1535-7163.Mct-08-1008 |
0.361 |
|
| 2009 |
Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Research. 69: 3910-7. PMID 19383925 DOI: 10.1158/0008-5472.Can-08-0034 |
0.373 |
|
| 2009 |
Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Molecular Cancer Therapeutics. 8: 947-58. PMID 19372568 DOI: 10.1158/1535-7163.Mct-08-0981 |
0.312 |
|
| 2009 |
Andreeff M, Fiegl M, Konopleva M, Korchin B, Kaluarachchi K, Bornmann WG, Guthrie PH, Harmancey R, Taegtmeyer H, Samudio IJ. Pharmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia. Blood. 114: 3779-3779. DOI: 10.1182/Blood.V114.22.3779.3779 |
0.329 |
|
| 2009 |
Donato NJ, Sun H, Kapuria V, Peterson LF, Bartholomeusz G, Bornmann WG, Talpaz M. WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells. Blood. 114: 3303-3303. DOI: 10.1182/Blood.V114.22.3303.3303 |
0.365 |
|
| 2009 |
Kapuria V, Peterson LF, Bornmann W, Talpaz M, Donato NJ. Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130. Blood. 114: 2907-2907. DOI: 10.1182/Blood.V114.22.2907.2907 |
0.36 |
|
| 2009 |
Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. APcK 110, a novel Inhibitor of Kit, Extends Survival of NOD-SCID Mice in An AML Xenograft Model. Blood. 114: 1045-1045. DOI: 10.1182/Blood.V114.22.1045.1045 |
0.308 |
|
| 2008 |
Ghosh P, Pal A, Shavrin A, Bornmann W, Gelovani JG, Alauddin MM. Synthesis of N3-substituted thymidine analogues for measurement of cellular kinase activity Medicinal Chemistry. 4: 503-512. PMID 18782048 DOI: 10.2174/157340608785700252 |
0.352 |
|
| 2008 |
Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase Journal of the National Cancer Institute. 100: 926-939. PMID 18577747 DOI: 10.1093/Jnci/Djn188 |
0.308 |
|
| 2008 |
Wagner MW, Long SL, Morales JC, Galindo CL, Garner HR, Bornmann WG, Boothman DA. Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses Journal of Biological Chemistry. 283: 21382-21393. PMID 18480061 DOI: 10.1074/Jbc.M709953200 |
0.323 |
|
| 2008 |
Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (Obatoclax) Cancer Research. 68: 3413-3420. PMID 18451169 DOI: 10.1158/0008-5472.Can-07-1919 |
0.323 |
|
| 2008 |
Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (London, England : 1993). 16: 460-7. PMID 18334220 DOI: 10.1016/J.Str.2007.12.016 |
0.308 |
|
| 2008 |
Yamaguchi H, Ding Y, Lee JF, Zhang M, Pal A, Bornmann W, Yan DH, Hung MC. Interferon-inducible protein IFIXα inhibits cell invasion by upregulating the metastasis suppressor maspin Molecular Carcinogenesis. 47: 739-743. PMID 18247378 DOI: 10.1002/Mc.20423 |
0.329 |
|
| 2008 |
Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells Blood. 111: 3821-3829. PMID 18235045 DOI: 10.1182/Blood-2007-08-109330 |
0.332 |
|
| 2008 |
Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway Leukemia. 22: 808-818. PMID 18200035 DOI: 10.1038/Sj.Leu.2405098 |
0.34 |
|
| 2008 |
Peterson LF, Sun H, Bornmann W, Peng Z, Maxwell D, Donato N, Talpaz M. Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors Blood. 112: 3212-3212. DOI: 10.1182/Blood.V112.11.3212.3212 |
0.372 |
|
| 2008 |
Konopleva M, Tsao T, Ling X, Kojima K, Watt J, Mak DH, Verhaegen M, Bornmann W, Soengas M, Andreeff M. Activation of p53 Signaling Is Synergistically Enhanced by Bcl-2 Inhibition through Induction of Noxa and Bak/Bax Heterodimers Resulting in Apoptosis of AML Stem Cells Blood. 112: 2940-2940. DOI: 10.1182/Blood.V112.11.2940.2940 |
0.306 |
|
| 2007 |
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, ... Bornmann W, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. The Journal of Clinical Investigation. 117: 4044-54. PMID 18060038 DOI: 10.1172/Jci32373 |
0.347 |
|
| 2007 |
Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Tae JK, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma Cancer Research. 67: 10976-10983. PMID 18006843 DOI: 10.1158/0008-5472.Can-07-2667 |
0.362 |
|
| 2007 |
Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone Proceedings of the National Academy of Sciences of the United States of America. 104: 11832-11837. PMID 17609380 DOI: 10.1073/Pnas.0702176104 |
0.316 |
|
| 2007 |
Fernández A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein G. Rational drug redesign to overcome drug resistance in cancer therapy: Imatinib moving target Cancer Research. 67: 4028-4033. PMID 17483313 DOI: 10.1158/0008-5472.Can-07-0345 |
0.306 |
|
| 2007 |
Bartholomeusz G, Talpaz M, Bornmann W, Kong LY, Donato NJ. Degrasyn activates proteasomal-dependent degradation of c-Myc Cancer Research. 67: 3912-3918. PMID 17440106 DOI: 10.1158/0008-5472.Can-06-4464 |
0.302 |
|
| 2007 |
Faderl S, Bornmann W, Maxwell D, Peng Z, Van Q, Liu Z, Verstovsek S, Ferrajoli A, Kantarjian HM, Estrov Z. Molecular targeting in acute myeloid leukemia (AML) therapy: APcK110 is a new inhibitor of c-Kit activity in AML blasts Journal of Clinical Oncology. 25: 7019-7019. DOI: 10.1200/Jco.2007.25.18_Suppl.7019 |
0.373 |
|
| 2007 |
Kapuria V, Bartholomeusz G, Kong L, Bornmann W, Peng Z, Pal A, Maxwell D, Talpaz M, Donato N. A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling. Blood. 110: 1556-1556. DOI: 10.1182/Blood.V110.11.1556.1556 |
0.352 |
|
| 2007 |
Donato N, Kapuria V, Sun H, Maxwell D, Bartholomeusz G, Bornmann W, Peng Z, Pal A, Talpaz M. Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation. Blood. 110: 1003-1003. DOI: 10.1182/Blood.V110.11.1003.1003 |
0.357 |
|
| 2006 |
Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML Cell Cycle. 5: 2778-2786. PMID 17172851 DOI: 10.4161/Cc.5.23.3520 |
0.304 |
|
| 2006 |
Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J. Pyridone 6, a Pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells Cancer Research. 66: 9714-9721. PMID 17018630 DOI: 10.1158/0008-5472.Can-05-4280 |
0.342 |
|
| 2006 |
Pal A, Glekas A, Doubrovin M, Balatoni J, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, Larson SM, Bornmann W, Gelovani JG. Molecular Imaging of EGFR kinase activity in tumors with 124 I-Labeled small molecular tracer and positron emission tomography Molecular Imaging and Biology. 8: 262-277. PMID 16897320 DOI: 10.1007/S11307-006-0049-0 |
0.327 |
|
| 2006 |
Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 103: 9244-9. PMID 16754879 DOI: 10.1073/Pnas.0600001103 |
0.338 |
|
| 2006 |
Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Molecular Cancer Therapeutics. 5: 1325-34. PMID 16731766 DOI: 10.1158/1535-7163.Mct-05-0494 |
0.307 |
|
| 2006 |
Wendel HG, De Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition Proceedings of the National Academy of Sciences of the United States of America. 103: 7444-7449. PMID 16651519 DOI: 10.1073/Pnas.0602402103 |
0.345 |
|
| 2006 |
Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RHI, Dunner K, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells Cancer Research. 66: 3773-3781. PMID 16585204 DOI: 10.1158/0008-5472.Can-05-2961 |
0.344 |
|
| 2006 |
O'Brian CA, Chu F, Bornmann WG, Maxwell DS. Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery? Expert Review of Anticancer Therapy. 6: 175-86. PMID 16445370 DOI: 10.1586/14737140.6.2.175 |
0.317 |
|
| 2006 |
Donato NJ, Wu J, Bornmann W, Talpaz M. Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance. Blood. 108: 4819-4819. DOI: 10.1182/Blood.V108.11.4819.4819 |
0.343 |
|
| 2006 |
Kapuria V, Bartholomeusz G, Bornmann W, Kong LY, Talpaz M, Donato NJ. Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism. Blood. 108: 3423-3423. DOI: 10.1182/Blood.V108.11.3423.3423 |
0.35 |
|
| 2006 |
Maxwell DS, Pal A, Peng Z, Shavrin A, Faderl S, Harris D, Van Q, Liu Z, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian HM, Estrov Z, Bornmann WG. Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia. Blood. 108: 1906-1906. DOI: 10.1182/Blood.V108.11.1906.1906 |
0.374 |
|
| 2006 |
Faderl S, Bornmann W, Maxwell D, Pal A, Peng Z, Shavrin A, Harris D, Van Q, Zhiming L, Verstovsek S, Manshouri T, Ferrajoli A, Kantarjian HM, Estrov Z. APCK110, a Novel and Potent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferation of Acute Myeloid Leukemia (AML) Cells. Blood. 108: 153-153. DOI: 10.1182/Blood.V108.11.153.153 |
0.37 |
|
| 2005 |
Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Medicine. 11: 731-9. PMID 15980865 DOI: 10.1038/Nm1265 |
0.306 |
|
| 2004 |
Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, Hayes PA, Dy BM, Heaney ML, Philips MR, Bornmann WG, Sirotnak FM, Scheinberg DA. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. The Journal of Clinical Investigation. 114: 1107-16. PMID 15489958 DOI: 10.1172/Jci22269 |
0.329 |
|
| 2004 |
Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate Leukemia. 18: 1352-1356. PMID 15201856 DOI: 10.1038/Sj.Leu.2403416 |
0.349 |
|
| 2003 |
Kuehne ME, Bornmann WG, Markó I, Qin Y, LeBoulluec KL, Frasier DA, Xu F, Mulamba T, Ensinger CL, Borman LS, Huot AE, Exon C, Bizzarro FT, Cheung JB, Bane SL. Syntheses and biological evaluation of vinblastine congeners Organic and Biomolecular Chemistry. 1: 2120-2136. PMID 12945903 DOI: 10.1039/B209990J |
0.645 |
|
| 2001 |
Stachel SJ, Chul Bom Lee, Spassova M, Chappell MD, Bornmann WG, Danishefsky SJ, Chou TC, Guan Y. On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process: Total synthesis and comparative in vivo evaluations of the 15-Aza epothilones Journal of Organic Chemistry. 66: 4369-4378. PMID 11397179 DOI: 10.1021/Jo010275C |
0.305 |
|
| 1998 |
Chou TC, Depew KM, Zheng YH, Safer ML, Chan D, Helfrich B, Zatorska D, Zatorski A, Bornmann W, Danishefsky SJ. Reversal of anticancer multidrug resistance by the ardeemins. Proceedings of the National Academy of Sciences of the United States of America. 95: 8369-74. PMID 9653193 DOI: 10.1073/Pnas.95.14.8369 |
0.313 |
|
| 1997 |
Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proceedings of the National Academy of Sciences of the United States of America. 94: 6099-103. PMID 9177176 DOI: 10.1073/Pnas.94.12.6099 |
0.338 |
|
| 1993 |
Borman LS, Bornmann WG, Kuehne ME. Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20′-vinblastine congeners that lack antimicrotubule activity Cancer Chemotherapy and Pharmacology. 31: 343-349. PMID 8431967 DOI: 10.1007/Bf00686146 |
0.589 |
|
| 1992 |
Deecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies Brain Research. 571: 242-247. PMID 1377086 DOI: 10.1016/0006-8993(92)90661-R |
0.532 |
|
| 1992 |
Bornmann WG, Kuehne ME. A common intermediate providing syntheses of ψ-tabersonine, coronaridine, iboxyphylline, ibophyllidine, vinamidine, and vinblastine Journal of Organic Chemistry. 57: 1752-1760. DOI: 10.1021/Jo00032A029 |
0.577 |
|
| 1991 |
Kuehne ME, Matson PA, Bornmann WG. Enantioselective syntheses of vinblastine, leurosidine, vincovaline, and 20′-epi-vincovaline Journal of Organic Chemistry. 56: 513-528. DOI: 10.1021/Jo00002A008 |
0.587 |
|
| 1989 |
Kuehne ME, Bornmann WG. Syntheses of 20′-deoxyvinblastine, 20′-deoxyleurosidine, 20′-deoxyvincovaline, 20′-epi-20′-deoxyvincovaline, and 20′-deoxyvincristine and its 20′-epimer through racemic and enantioselectively generated intermediates. New syntheses of D/E-cis- and -trans-ψ-vincadifformines and D/E-cis- and -trans-20-epi-ψ-vincadifformines Journal of Organic Chemistry. 54: 3407-3420. DOI: 10.1021/Jo00275A029 |
0.552 |
|
| 1989 |
Spitzer T, Kuehne ME, Bornmann W, Anklin C. Heteronuclear correlation via spin-locked zero- and multiple-quantum coherences Journal of Magnetic Resonance (1969). 84: 654-657. DOI: 10.1016/0022-2364(89)90134-0 |
0.495 |
|
| 1989 |
KUEHNE ME, BORNMANN WG, PARSONS WH, SPITZER TD, BLOUNT JF, ZUBIETA J. ChemInform Abstract: Total Syntheses of (.+-.)-Cephalotaxine (Ia) and (.+-.)-8-Oxocephalotaxine (Ib). Cheminform. 20. DOI: 10.1002/chin.198901265 |
0.531 |
|
| 1988 |
Kuehne ME, Bornmann WG, Parsons WH, Spitzer TD, Blount JF, Zubieta J. Total syntheses of (.+-.)-cephalotaxine and (.+-.)-8-oxocephalotaxine The Journal of Organic Chemistry. 53: 3439-3450. DOI: 10.1021/Jo00250A008 |
0.571 |
|
| 1988 |
Kuehne ME, Bornmann WG, Parsons WH, Spitzer TD, Blount JF, Zubieta J. Total syntheses of (±)-cephalotaxine and (±)-8-oxocephalotaxine Journal of Organic Chemistry. 53: 3439-3450. |
0.463 |
|
| 1987 |
Kuehne ME, Podhorez DE, Mulamba T, Bornmann WG. Biomimetic alkaloid syntheses. 15. Enantioselective syntheses with epichlorohydrin: total syntheses of (+)-, (-)- and (.+-.)-vindoline and a synthesis of (-)-vindorosine Journal of Organic Chemistry. 52: 347-353. DOI: 10.1021/Jo00379A006 |
0.595 |
|
| 1987 |
Kuehne ME, Zebovitz TC, Bornmann WG, Marko I. Three routes to the critical C16'-C14' parf relative stereochemistry of vinblastine. Syntheses of 20'-desethyl-20'-deoxyvinblastine, and 20'-desethyl-20'-deoxyvincovaline Journal of Organic Chemistry. 52: 4340-4349. DOI: 10.1021/Jo00228A035 |
0.541 |
|
| 1987 |
KUEHNE ME, PODHOREZ DE, MULAMBA T, BORNMANN WG. ChemInform Abstract: Biomimetic Alkaloid Syntheses. Part 15. Enantioselective Syntheses with Epichlorohydrin: Total Syntheses of (+)-, (-)-, and (.+-.)-Vindoline (I) and a Synthesis of (-)-Vindorosine (II). Cheminform. 18. DOI: 10.1002/chin.198735339 |
0.545 |
|
| 1987 |
Kuehne ME, Zebovitz TC, Bornmann WG, Marko I. Three routes to the critical C16′-C14′ parf relative stereochemistry of vinblastine. Syntheses of 20′-desethyl-20′-deoxyvinblastine and 20′-desethyl-20′-deoxyvincovaline Journal of Organic Chemistry. 52: 4340-4349. |
0.53 |
|
| 1987 |
Kuehne ME, Podhorez DE, Mulamba T, Bornmann WG. Biomimetic alkaloid syntheses. 15. Enantioselective syntheses with epichlorohydrin: Total syntheses of (+)-, (-)-, and (±)-vindoline and a synthesis of (-)-vindorosine Journal of Organic Chemistry. 52: 347-353. |
0.533 |
|
| 1986 |
Kuehne ME, Bornmann WG, Earley WG, Marko I. Studies in biomimetic alkaloid syntheses. 14. Controlled, selective syntheses of catharanthine and tabersonine, and related desethyl compounds, through generation of 15-oxosecodine intermediates Journal of Organic Chemistry. 51: 2913-2927. DOI: 10.1021/Jo00365A012 |
0.586 |
|
| 1986 |
Kuehne ME, Bornmann WG, Earley WG, Marko I. Studies in biomimetic alkaloid syntheses. 14. Controlled, selective syntheses of catharanthine and tabersonine, and related desethyl compounds, through generation of 15-oxosecodine intermediates Journal of Organic Chemistry. 51: 2913-2927. |
0.547 |
|
| 1985 |
Kuehne ME, Bohnert JC, Bornmann WG, Kirkemo CL, Kuehne SE, Seaton PJ, Zebovitz TC. Biomimetic syntheses of indole alkaloids. 11. Syntheses of .beta.-carboline and indoloazepine intermediates Journal of Organic Chemistry. 50: 919-924. DOI: 10.1021/Jo00207A001 |
0.57 |
|
| 1985 |
Kuehne ME, Bohnert JC, Bornmann WG, Kirkemo CL, Kuehne SE, Seaton PJ, Zebovitz TC. BIOMIMETIC SYNTHESES OF INDOLE ALKALOIDS. 11. SYNTHESES OF β-CARBOLINE AND INDOLOAZEPINE INTERMEDIATES Cheminform. 16. DOI: 10.1002/Chin.198535326 |
0.567 |
|
| 1985 |
Kuehne ME, Bohnert JC, Bornmann WG, Kirkemo CL, Kuehne SE, Seaton PJ, Zebovitz TC. Biomimetic syntheses of indole alkaloids. 11. Syntheses of β-carboline and indoloazepine intermediates Journal of Organic Chemistry. 50: 919-924. |
0.526 |
|
| Show low-probability matches. |